Price$2.04-0.17 (-7.69%)
2026-07-162026-10-16
News · 26 weeks55-89%
2026-04-192026-10-11
Mix1690d
- Insider9(56%)
- SEC Filings3(19%)
- Earnings2(13%)
- Offering1(6%)
- Other1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Sera Prognostics Inc.4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $14,044 worth of shares (7,022 units at $2.00), decreasing direct ownership by 0.83% to 837,848 units (SEC Form 4) to satisfy withholding tax4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin sold $4,380 worth of shares (2,190 units at $2.00), decreasing direct ownership by 1% to 159,566 units (SEC Form 4) to satisfy withholding tax4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Commercial Officer Anderson Dyaarl Lee Jr. sold $3,600 worth of shares (1,800 units at $2.00), decreasing direct ownership by 2% to 76,198 units (SEC Form 4) (withholding tax)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Medical Officer Inglis Tiffany Eul Davis sold $972 worth of shares (486 units at $2.00), decreasing direct ownership by 0.53% to 91,589 units (SEC Form 4) to satisfy withholding obligation4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $40,278 worth of shares (20,139 units at $2.00), decreasing direct ownership by 2% to 844,870 units (SEC Form 4) (for withholding tax)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Aerts Austin4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gleason Scott3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Financial Officer Gleason Scott was granted 117,924 shares (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- PR1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from Sera Prognostics, and PRIME trial results showing early, low-cost intervention can cut the earliest preterm births by more than half.SALT LAKE CITY and LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Preterm birth affects about 1 in 10 U.S. pregnancies. It's one of the most common pregnancy complications. It's also one nobody warns you about. Yet most expecting mothers never learn their own risk until something goes
- SECSera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICERSALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera. Most recently, he served as Vice President of Investor Relations and Treasury at Neogen Corporation and previously served as CFO of LarmorBio and NX Prenatal. He also served as th
- SECSEC Form 10-Q filed by Sera Prognostics Inc.10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSSALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026. Key Second Quarter and Recent Highlights:Advanced Commercial Adoption Strategy with Fourth Partnership Program Launch: In August 2026, we launched fourth partnership program, expanding implementation of PreTRM® Test-guided care through a state-based initiative with a national payer. We also exceeded our 2026 payer eng
- PRSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026SALT LAKE CITY, July 29, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter fiscal year 2026 financial results on Wednesday August 12, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
- INSIDERDirector Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Capone Mark Christopher was granted 44,379 shares (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- PRPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population --SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions. Because NICU care
- INSIDERSEC Form 3 filed by new insider Capone Mark Christopher3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
SERA FAQ
7 questionsWhat does Sera Prognostics Inc. do?
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Where does SERA stock trade?
Sera Prognostics Inc. (SERA) is listed on NASDAQ.What sector and industry is SERA in?
Sera Prognostics Inc. operates in the Health Care sector, Medical Specialities industry.When did Sera Prognostics Inc. go public?
Sera Prognostics Inc. (SERA) completed its IPO in 2021.What are analysts saying about SERA?
Sera Prognostics Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $600.00 price target on 2026-06-04. Recent price targets range from $400.00 to $1900.00.What companies are similar to SERA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare SERA side-by-side with any of them on Quantisnow.How can I track SERA on Quantisnow?
Quantisnow aggregates Sera Prognostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SERA to receive live email and push alerts on every new disclosure.